# TE-KG Agent Page: 13-Question English Baseline

Generated: 2026-07-28T08:38:23+00:00

## Protocol

- Nine common or edge questions used the four-stage DeepThink workflow.
- Four interpretive/report questions used the six-stage Agent workflow.
- All questions were asked in English for reviewer-facing consistency.
- Answers below are reproduced in full without editorial correction or rerun-to-pass cleanup.
- The reasoning section records only workflow artifacts and reasoning messages exposed by TE-KG. It is not hidden model chain-of-thought.
- Stage timing is the measured LLM HTTP-call duration from diagnostics. Event records do not contain timestamps, so unavailable non-LLM wall time is not invented.

## Overall Results

- Cases recorded: 13
- Endpoint-complete cases: 13/13
- Sum of end-to-end case duration: 1,878,784 ms (1878.8 s)

| Case | Mode | Completed | Total time | Plugins | Answer characters |
|---|---|---:|---:|---|---:|
| AQ01 | DeepThink | True | 20,264 ms (20.3 s) | Entity Resolver, Sequence Plugin, Citation Resolver | 124 |
| AQ02 | DeepThink | True | 17,218 ms (17.2 s) | Entity Resolver, Tree Plugin | 130 |
| AQ03 | DeepThink | True | 25,362 ms (25.4 s) | Entity Resolver, Genome Plugin | 369 |
| AQ04 | DeepThink | True | 25,900 ms (25.9 s) | Entity Resolver, Expression Plugin | 490 |
| AQ05 | DeepThink | True | 26,738 ms (26.7 s) | Entity Resolver, Graph Plugin, Citation Resolver | 1,382 |
| AQ06 | DeepThink | True | 33,995 ms (34.0 s) | Entity Resolver, Literature Plugin, Citation Resolver | 1,038 |
| AQ07 | DeepThink | True | 21,213 ms (21.2 s) | Entity Resolver, Site Navigator Plugin | 503 |
| AQ08 | Agent | True | 305,845 ms (305.8 s) | Entity Resolver, Graph Analytics Plugin, Graph Plugin, Literature Plugin, Cypher Explorer Plugin, Literature Reading Plugin, Citation Resolver | 3,634 |
| AQ09 | Agent | True | 474,410 ms (474.4 s) | Entity Resolver, Graph Plugin, Literature Plugin, Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin, Citation Resolver | 6,181 |
| AQ10 | Agent | True | 362,335 ms (362.3 s) | Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Citation Resolver | 8,807 |
| AQ11 | DeepThink | True | 25,722 ms (25.7 s) | Entity Resolver, Sequence Plugin | 117 |
| AQ12 | DeepThink | True | 45,742 ms (45.7 s) | Entity Resolver, Graph Plugin, Sequence Plugin | 434 |
| AQ13 | Agent | True | 494,040 ms (494.0 s) | Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin, Citation Resolver | 7,317 |

## Actual Plugin Coverage

| Plugin | Expected by matrix | Observed in events |
|---|---:|---:|
| Entity Resolver | Yes | Yes |
| Sequence Plugin | Yes | Yes |
| Tree Plugin | Yes | Yes |
| Genome Plugin | Yes | Yes |
| Expression Plugin | Yes | Yes |
| Graph Plugin | Yes | Yes |
| Literature Plugin | Yes | Yes |
| Site Navigator Plugin | Yes | Yes |
| Graph Analytics Plugin | Yes | Yes |
| Cypher Explorer Plugin | Yes | Yes |
| Literature Reading Plugin | Yes | Yes |
| Citation Resolver | Yes | Yes |

## AQ01: sequence_lookup

**Question:** What is the consensus sequence length of L1HS, and what is the evidence source?

- Mode: DeepThink
- Completed: True
- End-to-end duration: 20,264 ms (20.3 s)
- Expected plugins: Entity Resolver, Sequence Plugin
- Actual plugins: Entity Resolver, Sequence Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_bc5ebc3aaf231051`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 5,510 ms (5.5 s) | 5,510 ms | ok |
| Planning | 1 | 4,047 ms (4.0 s) | 4,047 ms | ok |
| Executing | 1 | 3,778 ms (3.8 s) | 3,778 ms | ok |
| Writing | 1 | 6,733 ms (6.7 s) | 6,733 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":0}` |
| Sequence Plugin | ok | 3 ms (0.0 s) | `{"matched_records":1,"strict_matches":1,"broad_matches":0}` |
| Citation Resolver | ok | 0 ms (0.0 s) | `{"total":2,"pmid":0,"title_only":2}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: What is the consensus sequence length of L1HS and what is the source of that evidence?
2. **Understanding / artifact:** answer_goal: Provide the consensus sequence length of L1HS and cite the evidence source (e.g., publication or database).
3. **Planning / artifact:** execution_goal: Provide the consensus sequence length of L1HS and cite the evidence source.
4. **Planning / artifact:** rationale: The question asks for the consensus sequence length of L1HS and its evidence source. The Sequence Plugin is directly designed to retrieve Repbase-backed sequence records, including consensus length and references. No other plugins are needed because the intent is sequence-specific and explicit literature retrieval is not required. The Sequence Plugin can provide the length and the underlying references, which will then be processed by the Citation Resolver for stable citation output.
5. **Planning / artifact:** business_plugins: Sequence Plugin
6. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
7. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
8. **Executing / artifact:** reason: Entity resolution is complete. Need Sequence Plugin to retrieve the consensus sequence length of L1HS and its associated evidence source (e.g., RepBase reference).
9. **Executing / artifact:** gaps: Consensus sequence length and evidence source for L1HS not yet retrieved.
10. **Deep Think / tool_selected:** I will use Sequence Plugin to collect the next required evidence.
11. **Deep Think / tool_result:** Sequence Plugin completed. Scientific details are preserved below.
12. **Deep Think / tool_selected:** I will use Citation Resolver to collect the next required evidence.
13. **Deep Think / tool_result:** Citation Resolver completed. Scientific details are preserved below.

### Complete Answer

> The consensus sequence length of L1HS is 6064 base pairs, as reported in RepBase (Smit et al., 1995; Jurka & Gentles, 2005).

## AQ02: taxonomy_lookup

**Question:** What is the complete classification path of L1HS?

- Mode: DeepThink
- Completed: True
- End-to-end duration: 17,218 ms (17.2 s)
- Expected plugins: Entity Resolver, Tree Plugin
- Actual plugins: Entity Resolver, Tree Plugin
- Expected but not observed: None
- Request ID: `req_a27637a432841827`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 6,559 ms (6.6 s) | 6,559 ms | ok |
| Planning | 1 | 4,524 ms (4.5 s) | 4,524 ms | ok |
| Executing | 1 | 2,768 ms (2.8 s) | 2,768 ms | ok |
| Writing | 1 | 3,108 ms (3.1 s) | 3,108 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Tree Plugin | ok | 40 ms (0.0 s) | `{"paths":1}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: User asks for the complete classification path of the transposable element L1HS.
2. **Understanding / artifact:** answer_goal: Provide the complete classification hierarchy (e.g., order, superfamily, family, lineage) for the transposable element L1HS.
3. **Planning / artifact:** execution_goal: Provide the complete classification hierarchy for the transposable element L1HS.
4. **Planning / artifact:** rationale: The Tree Plugin is designed to retrieve TE lineage paths and classification context, which directly addresses the user's request for the complete classification path of L1HS.
5. **Planning / artifact:** business_plugins: Tree Plugin
6. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
7. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
8. **Executing / artifact:** reason: The user asked for the complete classification path of L1HS. The Entity Resolver has resolved the entity, but the classification hierarchy is still missing. The Tree Plugin is designed to retrieve TE lineage paths and will provide the required classification context.
9. **Executing / artifact:** gaps: Classification path for L1HS (e.g., order, superfamily, family, lineage) not yet retrieved.
10. **Deep Think / tool_selected:** I will use Tree Plugin to collect the next required evidence.
11. **Deep Think / tool_result:** Tree Plugin completed. Scientific details are preserved below.

### Complete Answer

> The complete classification path of L1HS is: TE → Retrotransposons → Non-LTR Retrotransposons (LINEs) → L1 (LINE-1) → L1PA → L1HS.

## AQ03: genome_lookup

**Question:** Where is L1HS located in the human genome? Clarify whether the returned coordinates are representative loci or a complete locus set.

- Mode: DeepThink
- Completed: True
- End-to-end duration: 25,362 ms (25.4 s)
- Expected plugins: Entity Resolver, Genome Plugin
- Actual plugins: Entity Resolver, Genome Plugin
- Expected but not observed: None
- Request ID: `req_e2211f7c755a6c46`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 10,108 ms (10.1 s) | 10,108 ms | ok |
| Planning | 1 | 6,739 ms (6.7 s) | 6,739 ms | ok |
| Executing | 1 | 4,619 ms (4.6 s) | 4,619 ms | ok |
| Writing | 1 | 3,682 ms (3.7 s) | 3,682 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Genome Plugin | ok | 1 ms (0.0 s) | `{"loci":1}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: User asks for the genomic location of L1HS in the human genome and wants clarification on whether provided coordinates are representative loci or a complete set.
2. **Understanding / artifact:** answer_goal: Provide the genomic coordinates (chromosome, start, end) of L1HS in the human genome, and explicitly state whether the coordinates represent a single representative locus (e.g., consensus sequence or reference insertion) or a complete set of all L1HS loci (e.g., all copies in the genome).
3. **Understanding / artifact:** warnings: L1HS is a retrotransposon present in hundreds to thousands of copies; coordinates may refer to a consensus sequence rather than a specific genomic locus.; Clarify whether the user expects a single reference coordinate (e.g., from RepeatMasker or RefSeq) or all mapped insertions.
4. **Planning / artifact:** execution_goal: Retrieve genomic coordinates for L1HS from the Genome Plugin and determine whether the returned coordinates are representative loci or a complete set.
5. **Planning / artifact:** rationale: The user asks for the genomic location of L1HS and a clarification on whether the coordinates are representative or complete. The Genome Plugin is designed to retrieve genomic hit summaries, representative loci, and JBrowse URLs, which directly addresses the question. The plugin description notes that it provides representative loci and sampled hits, which aligns with the need for clarification. Other plugins (e.g., Literature, Graph, Expression) are not required because the user did not explicitly request literature or broader relationships, and the question is focused solely on genomic coordinates. The explicit_literature_request is false, so Literature Plugin and Literature Reading Plugin are not selected. Citation Resolver is allowed to normalize any citations returned by the Genome Plugin.
6. **Planning / artifact:** business_plugins: Genome Plugin
7. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
8. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
9. **Executing / artifact:** reason: Genome Plugin is required to retrieve genomic coordinates for L1HS and clarify whether the returned coordinates represent representative loci or a complete locus set. Entity resolution is complete but no genomic data has been obtained yet.
10. **Executing / artifact:** gaps: Genomic coordinates (chromosome, start, end) for L1HS; Clarification on whether the coordinates are representative loci or a complete locus set
11. **Deep Think / tool_selected:** I will use Genome Plugin to collect the next required evidence.
12. **Deep Think / tool_result:** Genome Plugin completed. Scientific details are preserved below.
13. **Writing / artifact:** limitations: The coordinates are a single representative locus, not a comprehensive list of all L1HS insertions.; The total number of L1HS hits (1,620) is a count from the source database; actual number may vary with genome build and annotation method.; No citations were returned by the plugin; the provenance is from a JBrowse hit bundle.

### Complete Answer

> L1HS has a representative genomic locus at **chr1:231,646,101–231,652,225** (GRCh38, strand: -). This coordinate is a single representative locus (e.g., a reference insertion or consensus sequence) and **does not represent a complete set** of all L1HS insertions. The genome contains at least 1,620 total L1HS hits, but only one is provided as the representative locus.

## AQ04: expression_lookup

**Question:** In which normal tissues, normal cell lines, and cancer cell lines is L1HS most highly expressed?

- Mode: DeepThink
- Completed: True
- End-to-end duration: 25,900 ms (25.9 s)
- Expected plugins: Entity Resolver, Expression Plugin
- Actual plugins: Entity Resolver, Expression Plugin
- Expected but not observed: None
- Request ID: `req_7f264683e752cae6`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 9,803 ms (9.8 s) | 9,803 ms | ok |
| Planning | 1 | 6,597 ms (6.6 s) | 6,597 ms | ok |
| Executing | 1 | 3,403 ms (3.4 s) | 3,403 ms | ok |
| Writing | 1 | 5,871 ms (5.9 s) | 5,871 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":2,"alias_variants":3}` |
| Expression Plugin | ok | 32 ms (0.0 s) | `{"profiles":1}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: Identify the normal tissues, normal cell lines, and cancer cell lines where L1HS is most highly expressed.
2. **Understanding / artifact:** answer_goal: Provide a ranked list for each of the three categories (normal tissues, normal cell lines, cancer cell lines) showing the top entries with highest L1HS expression, along with expression levels or scores.
3. **Understanding / artifact:** warnings: Normal cell lines may be uncommon or derived from non-cancerous tissues; ensure definitions are clear.; Expression measurements across different data sources may use different normalization techniques, limiting direct comparability.; L1HS expression in normal tissues is typically low; highest expression might still be relatively low.
4. **Planning / artifact:** execution_goal: Use Expression Plugin to retrieve L1HS expression profiles across normal tissues, normal cell lines, and cancer cell lines, then rank the top entries for each category.
5. **Planning / artifact:** rationale: The question asks for expression data specifically. The Expression Plugin is designed to retrieve TE expression profiles and top tissue/cell contexts. No other plugins are needed because the question does not require graph relationships, literature, or sequence information. Citation Resolver can be used to normalize any citations returned from the Expression Plugin.
6. **Planning / artifact:** business_plugins: Expression Plugin
7. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
8. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
9. **Executing / artifact:** reason: All required evidence for ranking L1HS expression in normal tissues, normal cell lines, and cancer cell lines has not been collected yet. The Expression Plugin is planned to retrieve these expression profiles. No other plugins are needed at this point.
10. **Executing / artifact:** gaps: L1HS expression data for normal tissues (e.g., GTEx) is missing.; L1HS expression data for normal cell lines is missing.; L1HS expression data for cancer cell lines (e.g., CCLE) is missing.; Ranked lists for each category (normal tissues, normal cell lines, cancer cell lines) are not yet available.
11. **Deep Think / tool_selected:** I will use Expression Plugin to collect the next required evidence.
12. **Deep Think / tool_result:** Expression Plugin completed. Scientific details are preserved below.
13. **Writing / artifact:** limitations: Only the top context for each category is provided; no full ranked lists are available.; Expression values are from the Expression Plugin dataset; comparability across categories is limited.; Normal cell lines are derived from non-cancerous tissues; definitions may vary.

### Complete Answer

> Based on expression data from the Expression Plugin, L1HS expression is highest in the following contexts:
>
> - **Normal Tissue**: prostate gland (median of medians: 656.74, max of max: 835.16)
> - **Normal Cell Line**: foreskin fibroblast (median of medians: 3816.37, max of max: 8778.23)
> - **Cancer Cell Line**: Anaplastic large cell lymphoma (median of medians: 1899.76, max of max: 1967.62)
>
> These represent the top contexts in each category. No additional ranking information is available.

## AQ05: graph_relation

**Question:** Which diseases are related to L1HS in TE-KG? Treat graph relations as associations rather than proof of causality.

- Mode: DeepThink
- Completed: True
- End-to-end duration: 26,738 ms (26.7 s)
- Expected plugins: Entity Resolver, Graph Plugin
- Actual plugins: Entity Resolver, Graph Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_89978d5321260049`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 6,245 ms (6.2 s) | 6,245 ms | ok |
| Planning | 1 | 6,261 ms (6.3 s) | 6,261 ms | ok |
| Executing | 1 | 3,452 ms (3.5 s) | 3,452 ms | ok |
| Writing | 1 | 10,408 ms (10.4 s) | 10,408 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Graph Plugin | ok | 119 ms (0.1 s) | `{"relations":52,"entity_types":5,"strict_matches":52,"broad_matches":0,"Function":24,"Gene":8,"Protein":5,"RNA":3,"Disease":12}` |
| Citation Resolver | ok | 2 ms (0.0 s) | `{"total":29,"pmid":29,"title_only":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: Identify diseases associated with L1HS in the TE-KG, considering graph relations as associations, not causal proof.
2. **Understanding / artifact:** answer_goal: List diseases connected to L1HS in TE-KG, describing each association and any known mechanistic links, but without claiming causal proof.
3. **Understanding / artifact:** warnings: Treat all graph relations as associations, not proof of causality.; Avoid inferring causal direction from graph edges alone.
4. **Planning / artifact:** execution_goal: Retrieve diseases associated with L1HS from the TE-KG graph using the Graph Plugin, treating all graph relations as associations.
5. **Planning / artifact:** rationale: The question asks for diseases related to L1HS in TE-KG, emphasizing graph relations as associations. The Graph Plugin is the appropriate tool to retrieve local relationships between L1HS and diseases. No other plugins are needed because the question does not require literature, analytics, taxonomy, expression, genome, or sequence data. Citation Resolver is allowed to normalize any provenance from graph results.
6. **Planning / artifact:** business_plugins: Graph Plugin
7. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
8. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
9. **Executing / artifact:** reason: The question asks for diseases associated with L1HS in TE-KG. The Entity Resolver has resolved L1HS, but disease associations have not yet been retrieved. The Graph Plugin is required to retrieve the local graph relationships between L1HS and diseases from the TE-KG. Once obtained, we can summarize the associations, treating them as graph relations rather than causal proof.
10. **Executing / artifact:** gaps: No disease associations have been retrieved yet.; Graph relations connecting L1HS to diseases are needed to answer the question.
11. **Deep Think / tool_selected:** I will use Graph Plugin to collect the next required evidence.
12. **Deep Think / tool_result:** Graph Plugin completed. Scientific details are preserved below.
13. **Deep Think / tool_selected:** I will use Citation Resolver to collect the next required evidence.
14. **Deep Think / tool_result:** Citation Resolver completed. Scientific details are preserved below.

### Complete Answer

> Based on the TE-KG graph, L1HS is associated with the following diseases (treating all graph relations as associations, not proof of causality):
>
> - **Cancer**: L1HS mobilization in somatic tissues contributes to diseases such as cancer.
> - **Carcinoma**: Some LINE-1 loci can escape DNA methylation and become active, particularly in carcinomas.
> - **Colorectal cancer**: Certain colorectal cancers were excessively mutagenized by human-specific L1s.
> - **Disturbed spermatogenesis**: Hypomethylation in L1HS was detected in disturbed spermatogenesis.
> - **Genetic disease**: L1HS activity has the potential to cause disease; L1Hs retrotransposition occasionally leads to human genetic disorders.
> - **Lung cancer**: Hypomethylation of LINE-1 promoters in circulating DNA of lung cancer patients is more pronounced for the human-specific L1Hs family.
> - **Lung squamous cell carcinoma**: LSQCC exhibited the highest total levels of L1HS expression.
> - **Neural tube defect**: L1Hs hypomethylation in neuronal tissues is associated with NTD pathogenesis.
> - **Non-small cell lung cancer**: Hypomethylation of LINE-1 promoters was assessed in circulating DNA of non-small cell lung cancer patients.
> - **Schizophrenia**: L1HS transpositions are implicated as a genomic risk factor for schizophrenia.
> - **Systemic lupus erythematosu**: L1Hs loci are transcriptionally active in SLE neutrophils.

## AQ06: literature_lookup

**Question:** Which papers support an association between LINE-1 and cancer? Include available PMIDs or DOIs.

- Mode: DeepThink
- Completed: True
- End-to-end duration: 33,995 ms (34.0 s)
- Expected plugins: Entity Resolver, Literature Plugin
- Actual plugins: Entity Resolver, Literature Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_08d0a1d3233f50d9`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 3,273 ms (3.3 s) | 3,273 ms | ok |
| Planning | 1 | 9,320 ms (9.3 s) | 9,320 ms | ok |
| Executing | 1 | 2,605 ms (2.6 s) | 2,605 ms | ok |
| Writing | 1 | 11,944 ms (11.9 s) | 11,944 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":2,"alias_variants":0}` |
| Literature Plugin | ok | 6,603 ms (6.6 s) | `{"local_hits":0,"strict_local_hits":0,"broad_local_hits":0,"pubmed_candidates":166,"reviewed":8}` |
| Citation Resolver | ok | 0 ms (0.0 s) | `{"total":8,"pmid":8,"title_only":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: Which papers support an association between LINE-1 and cancer? Include available PMIDs or DOIs.
2. **Understanding / artifact:** answer_goal: List papers that report an association between LINE-1 (L1) elements and cancer, including PMIDs or DOIs when available.
3. **Planning / artifact:** execution_goal: Retrieve and list papers that support an association between LINE-1 (L1) elements and cancer, including PMIDs or DOIs.
4. **Planning / artifact:** rationale: The user explicitly asks for literature supporting an association between LINE-1 and cancer. Literature Plugin will retrieve relevant papers from local graph citations and PubMed, providing bibliographic identifiers. Citation Resolver will be used afterward to normalize and deduplicate citations.
5. **Planning / artifact:** business_plugins: Literature Plugin
6. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
7. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
8. **Executing / artifact:** reason: Entity resolution completed. Literature Plugin has not been executed yet. Need to retrieve papers supporting LINE-1 and cancer association.
9. **Executing / artifact:** gaps: No papers or citations retrieved supporting LINE-1 and cancer association.
10. **Deep Think / tool_selected:** I will use Literature Plugin to collect the next required evidence.
11. **Deep Think / tool_result:** Literature Plugin completed. Scientific details are preserved below.
12. **Deep Think / tool_selected:** I will use Citation Resolver to collect the next required evidence.
13. **Deep Think / tool_result:** Citation Resolver completed. Scientific details are preserved below.
14. **Writing / artifact:** limitations: The search query ("LINE1" AND "cancer" AND "evidence") may have retrieved papers that do not primarily address the association between LINE-1 and cancer. Only one paper in the evidence explicitly concerns LINE-1's involvement in cancer.; The evidence set is limited to 5 papers; many other potentially relevant papers exist (166 total PubMed hits) but were not reviewed in detail.; No DOI values were available from the supplied data; only PMIDs are provided.

### Complete Answer

> Based on a literature search for "LINE1" and "cancer", the following papers were retrieved. The paper that most directly supports an association between LINE-1 and cancer is:
>
> - **Long Interspersed Nuclear Elements 1 (LINE1): The chimeric transcript L1-MET and its involvement in cancer** (PMID: 31918342). Published in *Cancer genetics* (2020 Feb), this paper explicitly discusses LINE-1 and its role in cancer through a chimeric transcript.
>
> Other papers retrieved from the same search are listed below, but they do not centrally focus on LINE-1's association with cancer:
> - *Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis* (PMID: 26311717).
> - *Epidemiology and biology of early onset colorectal cancer* (PMID: 35221839).
> - *Sperm-Mediated Transgenerational Inheritance* (PMID: 29255455).
> - *Epigenetics of urothelial carcinoma* (PMID: 25421661).
>
> These papers appeared in the query results but their titles do not indicate a primary focus on LINE-1 and cancer. No DOIs were provided in the retrieved data.

## AQ07: site_navigation

**Question:** Which TE-KG page should I use to inspect L1HS expression data?

- Mode: DeepThink
- Completed: True
- End-to-end duration: 21,213 ms (21.2 s)
- Expected plugins: Entity Resolver, Site Navigator Plugin
- Actual plugins: Entity Resolver, Site Navigator Plugin
- Expected but not observed: None
- Request ID: `req_a5f9c1bb83494b56`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 5,940 ms (5.9 s) | 5,940 ms | ok |
| Planning | 1 | 5,210 ms (5.2 s) | 5,210 ms | ok |
| Executing | 1 | 5,250 ms (5.2 s) | 5,250 ms | ok |
| Writing | 1 | 4,594 ms (4.6 s) | 4,594 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Site Navigator Plugin | ok | 1 ms (0.0 s) | `{"routes":4}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: Which TE-KG page should I use to inspect L1HS expression data?
2. **Understanding / artifact:** answer_goal: Identify the specific TE-KG page (likely the L1HS gene/TE page) that contains expression data for L1HS.
3. **Planning / artifact:** execution_goal: Identify the specific TE-KG page (likely the L1HS gene/TE page) that contains expression data for L1HS.
4. **Planning / artifact:** rationale: The user asks for a navigation destination to inspect L1HS expression data. Site Navigator Plugin is designed to return TE-KG page or panel URLs, which directly answers the question. No other plugins are needed as the user is not requesting data retrieval, literature, or graph exploration.
5. **Planning / artifact:** business_plugins: Site Navigator Plugin
6. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
7. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
8. **Executing / artifact:** reason: The user asks which TE-KG page to use for L1HS expression data. The Site Navigator Plugin is designed to return TE-KG page or panel URLs, which directly answers the navigation question. We have resolved the entity L1HS via Entity Resolver, and now need the navigation destination.
9. **Executing / artifact:** gaps: Need the specific TE-KG page URL or panel identifier for L1HS expression data.
10. **Deep Think / tool_selected:** I will use Site Navigator Plugin to collect the next required evidence.
11. **Deep Think / tool_result:** Site Navigator Plugin completed. Scientific details are preserved below.
12. **Writing / artifact:** limitations: There was not enough direct structured or external evidence for a stronger answer.

### Complete Answer

> Use the [Expression detail summary](/TE-/expression_detail.php?te=L1HS#expression-detail-summary) page on TE-KG to inspect L1HS expression data. If you need a specific panel, you can also navigate to:
> - [Normal tissue expression](/TE-/expression_detail.php?te=L1HS#expression-detail-normal-tissue)
> - [Normal cell line expression](/TE-/expression_detail.php?te=L1HS#expression-detail-normal-cell-line)
> - [Cancer cell line expression](/TE-/expression_detail.php?te=L1HS#expression-detail-cancer-cell-line)

## AQ08: graph_analytics

**Question:** Which five transposable elements have the highest number of disease associations in the current TE-KG graph? Explain the ranking metric.

- Mode: Agent
- Completed: True
- End-to-end duration: 305,845 ms (305.8 s)
- Expected plugins: Entity Resolver, Graph Analytics Plugin
- Actual plugins: Entity Resolver, Graph Analytics Plugin, Graph Plugin, Literature Plugin, Cypher Explorer Plugin, Literature Reading Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_82fb0c5f02254262`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 4,588 ms (4.6 s) | 4,588 ms | ok |
| Planning | 1 | 7,037 ms (7.0 s) | 7,037 ms | ok |
| Collecting | 1 | 12,953 ms (13.0 s) | 12,953 ms | ok |
| ExecutingReview | 3 | 139,228 ms (139.2 s) | 62,833, 40,748, 35,647 ms | ok |
| Answer structure | 1 | 15,015 ms (15.0 s) | 15,015 ms | contains error |
| Integrating | 1 | 21,371 ms (21.4 s) | 21,371 ms | ok |
| Writing decision | 1 | 33,616 ms (33.6 s) | 33,616 ms | ok |
| Final writing | 2 | 32,154 ms (32.2 s) | 12,517, 19,637 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":3}` |
| Graph Analytics Plugin | empty | 8 ms (0.0 s) | `{"rows":0,"top_k":0,"graph_nodes":0,"graph_edges":0}` |
| Graph Plugin | empty | 247 ms (0.2 s) | `{"relations":0,"entity_types":0,"strict_matches":0,"broad_matches":0}` |
| Literature Plugin | ok | 6,057 ms (6.1 s) | `{"local_hits":0,"strict_local_hits":0,"broad_local_hits":0,"pubmed_candidates":59682,"reviewed":8}` |
| Cypher Explorer Plugin | ok | 15,621 ms (15.6 s) | `{"rows":5,"columns":2}` |
| Literature Reading Plugin | ok | 17,344 ms (17.3 s) | `{"reviewed_count":8,"selected_count":8,"claim_clusters":1,"supported_claims":0,"conflicting_claims":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / node_llm_result:** Identify the five transposable elements with the highest number of disease associations in the TE-KG graph and explain the ranking metric used.
2. **Question Understanding Node / analysis:** Recognized entities: TE via Transposable elements.
3. **Question Understanding Node / analysis:** Question type: graph_analytics. Complexity: multi_evidence_synthesis.
4. **Planning / node_llm_result:** Identify the five transposable elements with the highest number of disease associations in the current TE-KG graph and explain the ranking metric used.
5. **Planning Node / planning_step:** Current knowledge gap: entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted..
6. **Planning Node / planning_step:** Current knowledge gap: graph analytics because this question asks for global graph statistics, ranking, structure, or topology rather than a single local entity neighborhood..
7. **Planning Node / planning_step:** Resolve the canonical identity and alias boundaries for TE.
8. **Planning Node / planning_step:** Collect evidence for entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted.
9. **Planning Node / planning_step:** Collect evidence for graph analytics because this question asks for global graph statistics, ranking, structure, or topology rather than a single local entity neighborhood.
10. **Collecting / node_llm_result:** The question requires listing five TEs with highest disease associations from the TE-KG graph. The understanding stage resolved only a broad TE category. To query the graph, we need normalized specific TE entities. The Entity Resolver can provide canonical TE labels and aliases. After normalization, the Graph Analytics Plugin can compute the ranking. Hence, we proceed with Entity Resolver first.
11. **Evidence Collection Node / tool_selected:** I will stabilize entity names first so later evidence lookup does not drift across aliases.
12. **Evidence Collection Node / tool_result:** These aliases will be reused by the graph, literature, genome, and sequence layers.
13. **Evidence Collection Node / reflection:** I resolved 1 entities and prepared 3 strict alias variants so the downstream plugins can retry stable names before considering broad aliases. Next queued tools: Graph Analytics Plugin, Graph Plugin, Literature Plugin. Sufficiency: The research report still has required evidence layers that have not run.
14. **Evidence Collection Node / tool_selected:** I will use graph analytics now because this question is about ranking, counts, or global graph structure.
15. **Evidence Collection Node / tool_result:** This round did not produce a stable analytics ranking.
16. **Evidence Collection Node / reflection:** This tool did not produce a strong result. Next queued tools: Graph Plugin, Literature Plugin, Cypher Explorer Plugin. Sufficiency: The research report still has required evidence layers that have not run.
17. **Evidence Collection Node / tool_selected:** I will check the local graph first because it is the strongest initial layer for entity normalization, graph analytics, structured disease relations, literature synthesis.
18. **Evidence Collection Node / tool_result:** This round did not produce a strong local relation chain, so the answer should lean on literature or other supporting layers.
19. **Evidence Collection Node / reflection:** This tool did not produce a strong result. Next queued tools: Literature Plugin, Cypher Explorer Plugin. Sufficiency: The research report still has required evidence layers that have not run.
20. **Evidence Collection Node / tool_selected:** I will add literature evidence now because the current question still needs direct citation support.
21. **ExecutingReview / node_llm_result:** The Literature Plugin executed a broad PubMed query for '"TE"', retrieving 59,682 candidate records and reviewing 8 citations. The results are overwhelmingly about thermoelectric materials (e.g., Bi2Te3, AgCu(Se,S,Te)), unrelated to transposable elements. One paper discusses a tool for transposable element analysis (TE Density), but does not provide disease association rankings. No specific transposable elements or disease association counts were identified. The plugin output is not usable for answering the question.
22. **Evidence Collection Node / tool_result:** These papers mainly cover mechanism, cancer relevance, and disease evidence, which is enough to support the next synthesis step.
23. **Evidence Collection Node / reflection:** I combined the local paper evidence with an external PubMed search, found 59682 candidate records, and reviewed 8 citations that were worth carrying into the answer. Next queued tools: Cypher Explorer Plugin, Literature Reading Plugin. Sufficiency: The research report still has required evidence layers that have not run.
24. **Evidence Collection Node / tool_selected:** I will use the Cypher Explorer now because the fixed plugins may not cover the required graph pattern or aggregation.
25. **ExecutingReview / node_llm_result:** The Cypher Explorer Plugin successfully executed a read-only Cypher query against the TE-KG graph, returning the five transposable elements with the highest number of distinct disease associations. The ranking metric is the count of distinct Disease nodes directly connected to each TE node via any relationship type (COUNT(DISTINCT d)). Results: L1 (LINE-1) has 219 associations, SINE1/7SL (Alu) has 75, HERV has 26, SVA has 24, and LINE has 14.
26. **Evidence Collection Node / tool_result:** This read-only Cypher query expanded the graph exploration space beyond the fixed neighborhood plugins.
27. **Evidence Collection Node / reflection:** The Cypher Explorer generated a read-only aggregation query and returned 5 rows. Next queued tools: Literature Reading Plugin. Sufficiency: The research report still has required evidence layers that have not run.
28. **Evidence Collection Node / tool_selected:** I will synthesize the retrieved citations now so later steps receive grouped claims instead of a flat citation list.
29. **ExecutingReview / node_llm_result:** The Literature Reading Plugin searched PubMed using the query term '"TE"' and retrieved 8 citations, but none contained information about transposable elements, disease associations, or the TE-KG graph. The returned results were primarily materials science papers unrelated to the question. No evidence relevant to ranking transposable elements by disease associations was obtained.
30. **Evidence Collection Node / tool_result:** These grouped literature claims can be passed to later evidence synthesis or answer-writing nodes as JSON.
31. **Evidence Collection Node / reflection:** The literature reading layer reviewed 8 normalized citations and synthesized 1 claim clusters. No additional tools are currently queued. Sufficiency: The primary plugin returned enough evidence for this question type, so the route stopped at the minimal path.
32. **Evidence Collection Node / tool_selected:** I will normalize the citation layer now so the final answer can cite stable records.
33. **Evidence Collection Node / tool_result:** These normalized citation records will be reused by the final answer and the front-end reference UI.
34. **Integrating / node_llm_result:** Claim-evidence map generated.
35. **Evidence Synthesis Node / synthesizing:** I am now synthesizing the resolved entities, 4 identified knowledge gaps, and 11 evidence items into a coherent answer. Tools used: Entity Resolver, Graph Analytics Plugin, Graph Plugin, Literature Plugin, Cypher Explorer Plugin, Literature Reading Plugin, Citation Resolver.
36. **WritingDecision / node_llm_result:** Use the report plan structure to present a concise, graph‑centric answer. Begin by restating the question scope, then define the ranking metric explicitly (distinct Disease nodes per TE node). List the top five transposable elements with their exact disease counts from the Cypher Explorer results, in descending order. In the Evidence Paths section, note that the ranking is based on direct graph edges but relationship types and direction are unknown. In the Caveats section, highlight that the only supporting source is the TE‑KG graph via Cypher, explain the ambiguity of the 'TE' literature search and the resulting off‑topic evidence, and state limitations regarding graph completeness and lack of independent validation. Maintain a neutral, objective tone throughout.

### Complete Answer

> # Evidence‑walk draft report
>
> ## Question Scope
> The query requests the five transposable elements (TEs) with the most disease associations in the current TE‑KG graph and asks for an explanation of the ranking metric. The investigation is scoped to the graph’s internal entities and does not assess mechanisms or directionality of the associations.
>
> ## Ranking Method
> The ranking metric is the **count of distinct Disease nodes directly connected to a Transposable Element node**. The Cypher Explorer query processed in the graph is:
>
> ```cypher
> MATCH (te:TE)-[r]-(d:Disease)
> WITH te, count(DISTINCT d) AS diseaseCount
> ORDER BY diseaseCount DESC
> LIMIT 5
> RETURN te.name AS teName, diseaseCount
> ```
>
> Any relationship type (`-[r]-`) is allowed, and the direction of the edge is ignored; only the number of unique Disease nodes per TE node is counted. This means that associations may represent co‑occurrence, annotation, or other graph linkages, but their semantic nature is not filtered.
>
> ## Top Entities (Evidence from the Graph)
> Based solely on the Cypher Explorer output, the five transposable elements with the largest distinct disease connectivities are (in descending order of disease count):
>
> 1. **L1 (LINE‑1)** – 219 distinct Disease nodes  
> 2. **SINE1/7SL (Alu)** – 75 distinct Disease nodes  
> 3. **HERV (Human Endogenous Retrovirus)** – 26 distinct Disease nodes  
> 4. **SVA** – 24 distinct Disease nodes  
> 5. **LINE** – 14 distinct Disease nodes  
>
> No additional evidence from the literature package applies to these numbers; the data represent a snapshot of the TE‑KG graph at the time of the query.
>
> ## Evidence Paths
> The ranking is derived from direct graph edges, but the Cypher Explorer result does not specify the relationship types or their direction. Consequently, the evidence path for each TE‑disease pair is a generic graph connection without further qualification. No inter‑plugin routes, external literature confirmation, or provenance records are attached to the counts. All values originate from the **Cypher Explorer Plugin** output rows (claims 6‑10).
>
> ## Caveats
> - **Irrelevant literature**: The literature search for the abbreviation “TE” returned papers on thermoelectric materials (e.g., Bi₂Te₃ family) rather than transposable elements; these off‑topic results are excluded from the answer.  
> - **Lack of external validation**: The disease counts are based entirely on the TE‑KG graph; no independent data source confirms the associations.  
> - **Unknown relationship semantics**: The graph query matches any relationship type, so the nature of the connection (causal, correlative, or purely structural) is unknown.  
> - **Graph completeness**: The coverage of the TE‑KG graph is not assessed; the ranking reflects only the current graph state and may not include all known TE‑disease associations.  
> - **Ambiguity within classes**: The subfamily labeling (“LINE” vs. “L1 (LINE‑1)”) may reflect different levels of granularity; the counts come directly from the graph without further delineation.
>
> ## Answer
> The top five transposable elements by number of distinct disease associations in the TE‑KG graph are:
>
> - **L1 (LINE‑1)**: 219 diseases  
> - **SINE1/7SL (Alu)**: 75 diseases  
> - **HERV (Human Endogenous Retrovirus)**: 26 diseases  
> - **SVA**: 24 diseases  
> - **LINE**: 14 diseases  
>
> The ranking metric counts all distinct Disease nodes directly connected to each TE node via any relationship, without considering edge direction or semantic type. These values represent the graph’s internal connectivity and should be interpreted as a preliminary, un‑validated enumeration derived from the TE‑KG graph.

## AQ09: cypher_exploration

**Question:** List two-hop paths from L1HS through target genes to diseases, and show the relationship type at each step.

- Mode: Agent
- Completed: True
- End-to-end duration: 474,410 ms (474.4 s)
- Expected plugins: Entity Resolver, Cypher Explorer Plugin
- Actual plugins: Entity Resolver, Graph Plugin, Literature Plugin, Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_2e858a4b4243a506`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 9,472 ms (9.5 s) | 9,472 ms | ok |
| Planning | 1 | 10,458 ms (10.5 s) | 10,458 ms | ok |
| Collecting | 1 | 7,654 ms (7.7 s) | 7,654 ms | ok |
| ExecutingReview | 4 | 238,539 ms (238.5 s) | 59,058, 61,462, 86,628, 31,391 ms | ok |
| Sufficiency check | 4 | 31,866 ms (31.9 s) | 6,912, 4,824, 10,131, 9,999 ms | ok |
| Answer structure | 1 | 15,004 ms (15.0 s) | 15,004 ms | contains error |
| Integrating | 1 | 23,629 ms (23.6 s) | 23,629 ms | ok |
| Writing decision | 1 | 22,530 ms (22.5 s) | 22,530 ms | ok |
| Final writing | 1 | 38,795 ms (38.8 s) | 38,795 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Graph Plugin | ok | 50 ms (0.1 s) | `{"relations":20,"entity_types":2,"strict_matches":20,"broad_matches":0,"Disease":12,"Gene":8}` |
| Literature Plugin | ok | 1,598 ms (1.6 s) | `{"local_hits":14,"strict_local_hits":14,"broad_local_hits":0,"pubmed_candidates":0,"reviewed":14}` |
| Literature Reading Plugin | ok | 59,523 ms (59.5 s) | `{"reviewed_count":14,"selected_count":12,"claim_clusters":4,"supported_claims":8,"conflicting_claims":0}` |
| Cypher Explorer Plugin | empty | 14,534 ms (14.5 s) | `{"rows":0,"columns":0}` |
| Sequence Plugin | ok | 4 ms (0.0 s) | `{"matched_records":1,"strict_matches":1,"broad_matches":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / node_llm_result:** The user asks to list all two-hop paths starting from the transposable element L1HS, passing through target genes, and ending at diseases, and to show the relationship type for each step in the path.
2. **Question Understanding Node / analysis:** Recognized entities: L1HS via L1HS.
3. **Question Understanding Node / analysis:** Question type: mechanism. Complexity: mechanism_chain.
4. **Planning / node_llm_result:** List two-hop paths from L1HS through target genes to diseases, and show the relationship type at each step.
5. **Planning Node / planning_step:** Current knowledge gap: entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted..
6. **Planning Node / planning_step:** Current knowledge gap: structured relations because mechanism questions first need local graph relations that can connect te entities to functions, genes, mutations, proteins, rnas, or diseases..
7. **Planning Node / planning_step:** Resolve the canonical identity and alias boundaries for L1HS.
8. **Planning Node / planning_step:** Collect evidence for entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted.
9. **Planning Node / planning_step:** Collect evidence for structured relations because mechanism questions first need local graph relations that can connect te entities to functions, genes, mutations, proteins, rnas, or diseases.
10. **Collecting / node_llm_result:** No plugins have been executed yet. The primary goal is to produce two-hop paths from L1HS through target genes to diseases with relationship types. Entity normalization is a prerequisite for downstream graph and literature queries. According to the research plan and collection state, entity normalization is an active gap. The Entity Resolver is the appropriate next step to resolve L1HS into a canonical form with aliases, enabling subsequent Graph Plugin and Literature Plugin calls. After this, the Graph Plugin can retrieve local relationships, and if needed, Literature Plugin can provide citations. The Cypher Explorer Plugin may be considered later if graph exploration is insufficient, but it should not be called prematurely. No evidence is available yet; therefore, is_sufficient is false.
11. **Evidence Collection Node / tool_selected:** I will stabilize entity names first so later evidence lookup does not drift across aliases.
12. **Evidence Collection Node / tool_result:** These aliases will be reused by the graph, literature, genome, and sequence layers.
13. **Evidence Collection Node / reflection:** I resolved 1 entities and prepared 2 strict alias variants so the downstream plugins can retry stable names before considering broad aliases. Next queued tools: Graph Plugin, Literature Plugin, Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin. Sufficiency: The minimum evidence gate is still missing required dimensions.
14. **Evidence Collection Node / tool_selected:** I will check the local graph first because it is the strongest initial layer for entity normalization, structured relations, mechanism literature, graph exploration, literature synthesis.
15. **ExecutingReview / node_llm_result:** The Graph Plugin ran successfully and returned 20 direct L1HS-disease relations (BIO_RELATION), but no two-hop paths through target genes were found. The output does not contain the intermediate gene nodes or relationship types required to answer the question.
16. **Evidence Collection Node / tool_result:** These relations suggest that the next mechanism draft should focus on Disease, Gene.
17. **Evidence Collection Node / reflection:** I first collected 20 structured relations from the local graph, mainly across Disease, Gene. Next queued tools: Literature Plugin, Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin. Sufficiency: The minimum evidence gate is still missing required dimensions.
18. **Evidence Collection Node / tool_selected:** I will add literature evidence now because the current question still needs direct citation support.
19. **ExecutingReview / node_llm_result:** The Literature Plugin executed a PubMed search for ""L1HS" AND "path"" that returned 0 results. It retrieved 14 local records, including references to L1HS insertion databases, methylation profiling, somatic retrotransposition in colorectal tumors, and hypomethylation in lung cancer. However, no explicit two-hop paths L1HS->Gene->Disease with relationship types were provided, so the output is insufficient to directly answer the question.
20. **Evidence Collection Node / tool_result:** The current local literature is already strong enough to support a first evidence-backed answer.
21. **Evidence Collection Node / reflection:** I combined the local paper evidence with an external PubMed search, found 0 candidate records, and reviewed 14 citations that were worth carrying into the answer. Next queued tools: Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin. Sufficiency: The current evidence includes direct L1HS-to-gene and L1HS-to-disease relations, but lacks the gene-to-disease relationships needed to construct two-hop paths (L1HS -> target gene -> disease). Without these intermediate connections, the required paths cannot be enumerated, and the relationship types for the second step are unknown.
22. **Evidence Collection Node / tool_selected:** I will synthesize the retrieved citations now so later steps receive grouped claims instead of a flat citation list.
23. **ExecutingReview / node_llm_result:** The Literature Reading Plugin processed 14 citations and generated 4 claim clusters: L1HS retrotransposition in cancer (colorectal, lung), epigenetic L1HS changes linked to congenital diseases (neural tube defects, spermatogenesis), genomic catalogs and sequencing for polymorphic L1HS insertions, and mechanistic studies of the LINE-1 promoter affecting adjacent genes. All evidence is at the abstract/metadata level with no explicit two-hop paths or gene-disease relationship types provided.
24. **Evidence Collection Node / tool_result:** These grouped literature claims can be passed to later evidence synthesis or answer-writing nodes as JSON.
25. **Evidence Collection Node / reflection:** The literature reading layer reviewed 14 normalized citations and synthesized 4 claim clusters. Next queued tools: Cypher Explorer Plugin, Sequence Plugin. Sufficiency: The current evidence includes direct L1HS-to-gene and L1HS-to-disease relations, but lacks the gene-to-disease relationships needed to construct two-hop paths (L1HS -> target gene -> disease). Without these intermediate connections, the required paths cannot be enumerated, and the relationship types for the second step are unknown.
26. **Evidence Collection Node / tool_selected:** I will use the Cypher Explorer now because the fixed plugins may not cover the required graph pattern or aggregation.
27. **Evidence Collection Node / tool_result:** This read-only Cypher query expanded the graph exploration space beyond the fixed neighborhood plugins.
28. **Evidence Collection Node / reflection:** This tool did not produce a strong result. Next queued tools: Sequence Plugin. Sufficiency: The evidence includes L1HS-to-gene and L1HS-to-disease relations from the Graph Plugin, but lacks the necessary gene-to-disease relationships to complete two-hop paths (L1HS -> target gene -> disease). The Cypher Explorer Plugin attempted to find such paths but returned zero results, and no other remaining experts can provide these missing connections without violating the 'each expert at most once' rule.
29. **Evidence Collection Node / tool_selected:** I will inspect the sequence layer now because sequence-level facts are still required.
30. **ExecutingReview / node_llm_result:** Sequence Plugin confirmed L1HS as a Repbase-backed sequence record of 6064 bp, providing entity normalization and low-confidence keyword-derived structure hints (LTR, LINE). No gene or disease associations were found, so it does not contribute directly to the requested two-hop paths. It is a prerequisite for entity normalization.
31. **Evidence Collection Node / tool_result:** These sequence-backed records add consensus length, annotation, and structure hints that can stabilize TE-specific answers.
32. **Evidence Collection Node / reflection:** I matched 1 TE sequence records from the Repbase-aligned library and extracted consensus length, sequence, and structure hints. No additional tools are currently queued. Sufficiency: The collected evidence includes direct L1HS-to-gene and L1HS-to-disease relations from the Graph Plugin (8 genes, 12 diseases), and the Cypher Explorer attempted to find two-hop paths but returned 0 rows. However, to answer the question, we need gene-to-disease relations for the target genes (e.g., CDH11, CHRM3, etc.) to complete two-hop paths from L1HS through a gene to a disease, with relationship types at each step. These missing relations are not present in any plugin result, and no remaining registered expert can provide them without re-calling already-executed plugins (each expert at most once). Therefore, the evidence is insufficient.
33. **Evidence Collection Node / tool_selected:** I will normalize the citation layer now so the final answer can cite stable records.
34. **Evidence Collection Node / tool_result:** These normalized citation records will be reused by the final answer and the front-end reference UI.
35. **Integrating / node_llm_result:** Claim-evidence map generated.
36. **Evidence Synthesis Node / synthesizing:** I am now synthesizing the resolved entities, 5 identified knowledge gaps, and 31 evidence items into a coherent answer. Tools used: Entity Resolver, Graph Plugin, Literature Plugin, Literature Reading Plugin, Cypher Explorer Plugin, Sequence Plugin, Citation Resolver.
37. **WritingDecision / node_llm_result:** Begin with biological context of L1HS retrotransposon. Present available direct associations: L1HS to diseases and L1HS to target genes, as documented in the evidence. Explain that these are single-hop edges. Then, explicitly address the question's requirement for two-hop paths (L1HS → gene → disease) with relationship types. Highlight that the evidence package lacks valid gene-disease associations needed for the second hop. Conclude that no complete two-hop paths can be listed. All facts will be tied to citations from the evidence map; the gap will be directly quoted from the unsupported claims analysis.

### Complete Answer

> # Evidence-Walk Draft Report
>
> ## Background
> L1HS is a human-specific LINE-1 (Long INterspersed Element‑1) retrotransposon with a consensus length of 6064 bp, documented in Repbase (evidence_30; citation_36, citation_37). Its repetitive nature and mobilization capability have led to a large body of literature examining its contributions to human disease. The question asks for two‑hop paths that link L1HS through an intermediate target gene to a final disease endpoint, together with the relationship types at each step.
>
> ## Mechanism Chain
> ### Direct associations observed in the evidence
> The available data provide only **single‑hop** relationships (either L1HS → disease or L1HS → gene) that are classified as `BIO_RELATION`. No gene‑to‑disease edges were retrieved. The documented edges are:
>
> **L1HS to disease (first‑hop only)**  
> - **Cancer** – L1HS mobilization in somatic tissues contributes to diseases such as cancer (claim_1, evidence_1; PMID 25352549, 34425899).  
> - **Carcinoma** – Some LINE‑1 loci escape DNA methylation and become active, particularly in carcinomas (claim_2, evidence_2; PMID 36449162).  
> - **Colorectal cancer** – Certain colorectal cancers were excessively mutagenized by human‑specific L1s (claim_3, evidence_3; PMID 22968929).  
> - **Disturbed spermatogenesis** – Hypomethylation in L1HS was detected in disturbed spermatogenesis (claim_4, evidence_4; PMID 38759652).  
> - **Genetic disease** – L1HS activity has the potential to cause disease (claim_5, evidence_5; PMID 29390960) and L1Hs retrotransposition occasionally leads to human genetic disorders (claim_6, evidence_6; PMID 31853540).  
> - **Lung cancer** – Hypomethylation of LINE‑1 promoters in circulating DNA of lung cancer patients is more pronounced for the human‑specific L1Hs family (claim_7, evidence_7; PMID 27565927).  
> - **Lung squamous cell carcinoma** – LSQCC exhibited the highest total levels of L1HS expression (claim_8, evidence_8; PMID 41681929).  
> - **Neural tube defect** – L1Hs hypomethylation in neuronal tissues is associated with NTD pathogenesis (claim_9, evidence_9; PMID 26122653).  
> - **Non‑small cell lung cancer** – Hypomethylation of LINE‑1 promoters was assessed in circulating DNA of NSCLC patients (claim_10, evidence_10; PMID 27565927).  
> - **Schizophrenia** – L1HS transpositions are implicated as a genomic risk factor for schizophrenia (claim_11, evidence_11; PMID 26990047).  
> - **Systemic lupus erythematosus** – L1Hs loci are transcriptionally active in SLE neutrophils (claim_12, evidence_12; PMID 37165451).
>
> **L1HS to gene (potential first‑hop for a two‑hop path)**  
> - **CDH11** – targeted by somatic LINE‑1 insertions in colorectal tumors (claim_13, evidence_13; PMID 22968929).  
> - **CHRM3** – L1HS provides a novel promoter for CHRM3 (claim_14, evidence_14; PMID 19669628) and integrated into the gene (claim_15, evidence_15; PMID 19669628).  
> - **ODZ3** – targeted by somatic LINE‑1 insertions in colorectal tumors (claim_17, evidence_17; PMID 22968929).  
> - **PCM1** – targeted by somatic LINE‑1 insertions in colorectal tumors (claim_18, evidence_18; PMID 22968929).  
> - **PTPRM** – targeted by somatic LINE‑1 insertions in colorectal tumors (claim_19, evidence_19; PMID 22968929).  
> - **ROBO2** – targeted by somatic LINE‑1 insertions in colorectal tumors (claim_20, evidence_20; PMID 22968929).  
> - **Genes associated with neural functions and disease** – L1Hs elements integrate preferentially into such genes (claim_16, evidence_16; PMID 29327725).
>
> All graph‑derived claims are marked with the quality flag *association_not_causality*, indicating that the evidence supports an observed correlation rather than a proven causal mechanism.
>
> ## Evidence Review
> The evidence package consolidates 31 claims across seven plugins. The Graph Plugin contributed 20 claims covering L1HS–disease and L1HS–gene edges; support strength for each is **medium** (evidence_1–evidence_20). The Literature Plugin provided five independent literature records (evidence_21–evidence_25), and the Literature Reading Plugin synthesized three thematic claims (evidence_26–evidence_29) that connect L1HS retrotransposition to cancer, epigenetic changes to congenital diseases, and promoter studies to regulatory influences; these claims also carry *metadata_or_abstract_level* quality flags. The Sequence Plugin supplied high‑strength evidence that L1HS maps to a 6064 bp Repbase sequence (evidence_30, high support) and low‑strength keyword‑derived structure hints (evidence_31, low support). The Cypher Explorer Plugin returned empty, so no multi‑step graph traversal augmented the direct edges.
>
> ## Limitations
> - **Missing second‑hop data**: The evidence lacks any gene‑to‑disease relationship assertions. Therefore, complete two‑hop paths (L1HS → gene → disease) with explicit relationship types for each step cannot be constructed from the provided content (claim_evidence_map.unsupported_claims).
> - **Single‑hop only**: All existing claims represent direct `BIO_RELATION` edges. The presence of L1HS‑to‑gene edges does not guarantee a second hop, because no linking data from those genes to specific diseases are included (evidence_package.limitations).
> - **Quality caveats**: Graph‑based relationships carry the `association_not_causality` warning; literature syntheses are at the abstract/metadata level, precluding detailed mechanistic inference (evidence_walk.coverage_metrics).
> - **Plugin gap**: The Cypher Explorer Plugin returned empty, limiting the ability to uncover indirect paths that might have existed in the graph (evidence_package.metrics.empty_plugin_count).
>
> ## Answer
> **No two‑hop paths from L1HS through a target gene to a disease can be listed.** The evidence provides only direct associations between L1HS and diseases or between L1HS and particular genes, but it does not supply the required gene‑to‑disease associations that would complete the second step. Consequently, it is impossible to display a complete path with relationship types at each hop. The available single‑hop edges are summarized in the Mechanism Chain above; they may serve as starting points for further investigation when gene‑disease links become available.

## AQ10: literature_synthesis

**Question:** Synthesize papers supporting an association between LINE-1 and cancer. Organize the result by main findings, conflicts, and evidence gaps, and provide deduplicated references.

- Mode: Agent
- Completed: True
- End-to-end duration: 362,335 ms (362.3 s)
- Expected plugins: Entity Resolver, Literature Plugin, Literature Reading Plugin, Citation Resolver
- Actual plugins: Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_2269b965624f5224`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 9,314 ms (9.3 s) | 9,314 ms | ok |
| Planning | 1 | 12,919 ms (12.9 s) | 12,919 ms | ok |
| Collecting | 1 | 7,801 ms (7.8 s) | 7,801 ms | ok |
| ExecutingReview | 2 | 160,805 ms (160.8 s) | 84,493, 76,312 ms | ok |
| Sufficiency check | 1 | 8,486 ms (8.5 s) | 8,486 ms | ok |
| Answer structure | 1 | 15,014 ms (15.0 s) | 15,014 ms | contains error |
| Integrating | 1 | 10,507 ms (10.5 s) | 10,507 ms | ok |
| Writing decision | 1 | 18,837 ms (18.8 s) | 18,837 ms | ok |
| Final writing | 1 | 38,040 ms (38.0 s) | 38,040 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":2,"alias_variants":4}` |
| Literature Plugin | ok | 6,415 ms (6.4 s) | `{"local_hits":0,"strict_local_hits":0,"broad_local_hits":0,"pubmed_candidates":1303,"reviewed":8}` |
| Literature Reading Plugin | ok | 72,597 ms (72.6 s) | `{"reviewed_count":8,"selected_count":8,"claim_clusters":4,"supported_claims":3,"conflicting_claims":0}` |
| Graph Plugin | empty | 191 ms (0.2 s) | `{"relations":0,"entity_types":0,"strict_matches":0,"broad_matches":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / node_llm_result:** Synthesize literature evidence supporting an association between LINE-1 and cancer, organizing results by main findings, conflicts, evidence gaps, and providing deduplicated references.
2. **Question Understanding Node / analysis:** Recognized entities: cancer via cancer, LINE1 via LINE-1.
3. **Question Understanding Node / analysis:** Question type: literature. Complexity: multi_evidence_synthesis.
4. **Planning / node_llm_result:** Synthesize literature evidence supporting an association between LINE-1 and cancer, organizing results by main findings, conflicts, evidence gaps, and providing deduplicated references.
5. **Planning Node / planning_step:** Current knowledge gap: entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted..
6. **Planning Node / planning_step:** Current knowledge gap: literature evidence because the user explicitly asked for papers or literature support..
7. **Planning Node / planning_step:** Resolve the canonical identity and alias boundaries for cancer, LINE1.
8. **Planning Node / planning_step:** Collect evidence for entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted.
9. **Planning Node / planning_step:** Collect evidence for literature evidence because the user explicitly asked for papers or literature support.
10. **Collecting / node_llm_result:** No collected evidence yet. The research plan requires literature evidence first. The primary path starts with Literature Plugin to address the most critical gap: peer-reviewed citations supporting LINE-1-cancer association. Entity normalization is considered handled by the understanding stage; remaining gaps will be closed after literature retrieval.
11. **Evidence Collection Node / tool_selected:** I will stabilize entity names first so later evidence lookup does not drift across aliases.
12. **Evidence Collection Node / tool_result:** These aliases will be reused by the graph, literature, genome, and sequence layers.
13. **Evidence Collection Node / reflection:** I resolved 2 entities and prepared 4 strict alias variants so the downstream plugins can retry stable names before considering broad aliases. Next queued tools: Literature Plugin, Literature Reading Plugin, Graph Plugin. Sufficiency: The research report still has required evidence layers that have not run.
14. **Evidence Collection Node / tool_selected:** I will add literature evidence now because the current question still needs direct citation support.
15. **ExecutingReview / node_llm_result:** The Literature Plugin executed a PubMed search for '"LINE1" AND "cancer"', retrieving 1303 candidate records and selecting 8 citations for review. The output includes titles and PubMed metadata for 5 distinct papers: 'Long Interspersed Nuclear Elements 1 (LINE1): The chimeric transcript L1-MET and its involvement in cancer' (PMID 31918342), 'Transposable elements in cancer' (PMID 28642606), 'Advances in understanding LINE-1 regulation and function in the human genome' (PMID 40382218), 'Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells' (PMID 40291377), and 'LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities' (PMID 38092519). No abstracts or full-text content were provided. The evidence confirms the existence of literature on LINE-1 in cancer but lacks synthesis of main findings, conflicts, or evidence gaps; these would require further processing by the Literature Reading Plugin and Graph Plugin.
16. **Evidence Collection Node / tool_result:** These papers mainly cover mechanism, cancer relevance, and disease evidence, which is enough to support the next synthesis step.
17. **Evidence Collection Node / reflection:** I combined the local paper evidence with an external PubMed search, found 1303 candidate records, and reviewed 8 citations that were worth carrying into the answer. Next queued tools: Literature Reading Plugin, Graph Plugin. Sufficiency: The research report still has required evidence layers that have not run.
18. **Evidence Collection Node / tool_selected:** I will synthesize the retrieved citations now so later steps receive grouped claims instead of a flat citation list.
19. **ExecutingReview / node_llm_result:** The Literature Reading Plugin synthesized 8 normalized citations into 4 claim clusters, all with medium support strength, covering retrotransposition/epigenetic deregulation, L1-MET chimeric transcript, immune modulation, and developmental roles. Evidence is derived from literature synthesis of metadata/abstracts; no full-text analysis. No conflicting claims were identified, but evidence gaps exist: limited sample size, no experimental validation of immune or developmental claims in cancer context, and lack of structured disease relations or graph data.
20. **Evidence Collection Node / tool_result:** These grouped literature claims can be passed to later evidence synthesis or answer-writing nodes as JSON.
21. **Evidence Collection Node / reflection:** The literature reading layer reviewed 8 normalized citations and synthesized 4 claim clusters. Next queued tools: Graph Plugin. Sufficiency: The research report still has required evidence layers that have not run.
22. **Evidence Collection Node / tool_selected:** I will check the local graph first because it is the strongest initial layer for entity normalization, literature evidence, structured disease relations, literature synthesis.
23. **Evidence Collection Node / tool_result:** This round did not produce a strong local relation chain, so the answer should lean on literature or other supporting layers.
24. **Evidence Collection Node / reflection:** This tool did not produce a strong result. No additional tools are currently queued. Sufficiency: Literature synthesis from 8 citations covers main findings (LINE-1 retrotransposition in cancer, L1-MET oncogenic transcript, immune modulation via splicing variants, developmental context for misregulation), identifies no conflicts, and highlights evidence gaps. Deduplicated references are available. The Graph Plugin returned empty but is not required for this literature synthesis question.
25. **Evidence Collection Node / tool_selected:** I will normalize the citation layer now so the final answer can cite stable records.
26. **Evidence Collection Node / tool_result:** These normalized citation records will be reused by the final answer and the front-end reference UI.
27. **Integrating / node_llm_result:** Claim-evidence map generated.
28. **Evidence Synthesis Node / synthesizing:** I am now synthesizing the resolved entities, 4 identified knowledge gaps, and 9 evidence items into a coherent answer. Tools used: Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Citation Resolver.
29. **WritingDecision / node_llm_result:** Synthesize papers supporting an association between LINE-1 and cancer by organizing evidence around main findings: the L1-MET chimeric transcript as an oncogenic driver, retrotransposition and epigenetic deregulation, immune modulation, and developmental roles. Note that no conflicts were identified. Highlight evidence gaps such as medium support strength across items, absence of full-text details, duplicate citations, and reliance on metadata-level evidence. Maintain a cautious tone and avoid overstatement. Deduplicate references in the final output.

### Complete Answer

> # LINE-1 and Cancer: Evidence Synthesis
>
> ## 1. Question Scope
> The present report synthesizes published evidence on the association between the long interspersed nuclear element‑1 (LINE‑1, also referred to as L1) and cancer. The synthesis is based entirely on the evidence payload delivered by the Literature Plugin and the Literature Reading Plugin; no external sources, full‑text content, or network‑interaction data were reviewed. The report is organized around the principal findings, notes any conflicts (none were detected), and highlights evidence gaps. All references are deduplicated in the final list.
>
> ## 2. Evidence Inventory
> The evidence package comprises nine distinct claims, each supported by at least one piece of evidence from pubmed‑indexed literature. The strength of support is uniformly “medium” for all items, indicating that while the cited publications are relevant, they were evaluated only at the metadata or abstract level without access to full experimental details.
>
> The findings can be grouped into four thematic areas:
>
> ### 2.1 The L1‑MET Chimeric Transcript as an Oncogenic Driver
> - **Claim:** The L1‑MET chimeric transcript (formed by splicing between LINE‑1 and the MET proto‑oncogene) is a specific oncogenic driver that can be targeted to induce apoptosis [claim_7].
>   - Supported by a literature synthesis (Literature Reading Plugin) citing two papers: one that reviews the chimeric transcript and its involvement in cancer (PMID 31918342) [citation_10], and a second that demonstrates that inhibiting the LINE1‑derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells (PMID 40291377) [citation_11].
>
> ### 2.2 Retrotransposition and Epigenetic Deregulation as Common Cancer Events
> - **Claim:** LINE‑1 retrotransposition and epigenetic deregulation are common events in cancer that offer therapeutic opportunities [claim_6].
>   - Supported by a synthesis (Literature Reading Plugin) referencing four sources: a review on transposable elements in cancer (PMID 28642606) [citation_6], a recent review on LINE‑1 regulation (PMID 40382218) [citation_7], a specific article on LINE‑1 deregulation in cancers (PMID 38092519) [citation_8], and a review on targeting transposable elements in cancer (PMID 38936517) [citation_9].
>
> ### 2.3 Modulation of Immune Function by LINE‑1 Splicing Variants
> - **Claim:** LINE‑1 splicing variants modulate immune cell function, with implications for cancer immune evasion [claim_8].
>   - Supported by a single paper (PMID 35039641) [citation_12] that reports non‑canonical LINE‑1 transcript variants regulating T cell quiescence and exhaustion.
>
> ### 2.4 Developmental Roles of LINE‑1 as Context for Cancer Misregulation
> - **Claim:** LINE‑1 has essential developmental roles, providing context for its misregulation in cancer [claim_9].
>   - Supported by a study (PMID 39413784) [citation_13] showing that LINE‑1 cooperates with PRC2 to control nucleolar organization and repress an 8C‑like state in human embryonic stem cells.
>
> Additionally, the Literature Plugin returned five direct citations that correspond to the above themes, confirming the presence of relevant publications: PMID 31918342, PMID 28642606, PMID 40382218, PMID 40291377, and PMID 38092519.
>
> No conflicting claims were identified among the synthesized evidence. All nine claims are supported by at least one evidence item, and the evidence walk confirms a support edge for each claim.
>
> ## 3. Citation Assessment
> All claims are linked to at least one citation from pubmed. The citation map reveals that some references are cited multiple times. Most notably, the review “Transposable elements in cancer” (PMID 28642606) appears both in the direct Literature Plugin output (claim_2) and in the Literature Reading Plugin synthesis (claim_6). After deduplication, the unique pubmed references supporting the LINE‑1/cancer association are:
>
> 1. **PMID 31918342** – “Long Interspersed Nuclear Elements 1 (LINE1): The chimeric transcript L1‑MET and its involvement in cancer.” *Cancer genetics*, 2020 Feb.  
> 2. **PMID 28642606** – “Transposable elements in cancer.” *Nature reviews. Cancer*, 2017 Jul.  
> 3. **PMID 40382218** – “Advances in understanding LINE‑1 regulation and function in the human genome.” *Trends in genetics : TIG*, 2025 Jul.  
> 4. **PMID 40291377** – “Inhibition of the LINE1‑derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells.” *Molecular therapy. Nucleic acids*, 2025 Jun 10.  
> 5. **PMID 38092519** – “LINE‑1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities.” *Genes & development*, 2023 Dec 26.  
> 6. **PMID 38936517** – “Targeting transposable elements in cancer: developments and opportunities.” *Biochimica et biophysica acta. Reviews on cancer*, 2024 Sep.  
> 7. **PMID 35039641** – “LINE1 are spliced in non‑canonical transcript variants to regulate T cell quiescence and exhaustion.” *Nature genetics*, 2022 Feb.  
> 8. **PMID 39413784** – “LINE1 and PRC2 control nucleolar organization and repression of the 8C state in human ESCs.” *Developmental cell*, 2025 Jan 20.
>
> Every claim that appears in the report is traceable to at least one of these deduplicated references. The medium support strength across all items, combined with the metadata‑only review level, means that while the sources are credible, their precise conclusions (e.g., exact effect sizes, tissue specificity, clinical feasibility) cannot be fully assessed from the available data.
>
> ## 4. Gaps
> Several evidence gaps and limitations are present in the current synthesis:
>
> - **Uniform medium support strength:** All evidence items are rated “medium” because they derive from metadata or abstract‑level summaries rather than full‑text experimental validation. No study was examined in detail for its methodology, sample size, or statistical power.
> - **Absence of full‑text details:** The Literature Reading Plugin synthesizes claims from multiple citations, but it flags its output as “metadata_or_abstract_level,” meaning no full‑text experimental data were directly inspected. The mechanistic details (e.g., exactly how LINE‑1 products induce apoptosis in specific cancer types) remain unverified in this report.
> - **Missing network/interaction data:** The Graph Plugin returned empty, providing no protein‑interaction or pathway‑level information that could strengthen the mechanistic chain between LINE‑1 and cancer.
> - **Redundant citations:** Some references, such as PMID 28642606, appear in multiple claims. While this does not weaken the evidence, it reduces the apparent diversity of the literature base.
> - **Immune and developmental links are limited to single citations:** The claims concerning immune modulation (claim_8) and developmental roles (claim_9) each rely on a single publication. No additional corroborating references are available in the current evidence set, so those links must be considered preliminary and require independent validation.
> - **No formal statistical synthesis:** This report is a qualitative summary; no meta‑analysis or quantitative effect‑size estimation was performed.
>
> These limitations mean that the synthesis represents a cautious, bounded overview of published titles and abstracts. High‑confidence therapeutic claims or definitive causal attributions cannot be made on this basis.
>
> ## 5. Answer
> **Main findings:** Published literature, assessed at the metadata/abstract level, consistently indicates a multi‑faceted association between LINE‑1 and cancer. The evidence organizes into four themes:
> 1. The L1‑MET chimeric transcript functions as a specific oncogenic driver whose inhibition can induce apoptosis (PMID 31918342; PMID 40291377).  
> 2. LINE‑1 retrotransposition and epigenetic deregulation are widespread in cancer and represent potential therapeutic targets (PMID 28642606; PMID 40382218; PMID 38092519; PMID 38936517).  
> 3. Non‑canonical splicing variants of LINE‑1 may modulate T‑cell quiescence and exhaustion, thus potentially influencing anti‑tumor immunity (PMID 35039641).  
> 4. The essential developmental roles of LINE‑1 (e.g., in nucleolar organization with PRC2) provide a context for its misregulation in tumorigenesis (PMID 39413784).
>
> **Conflicts:** No contradictory findings were detected in the assembled evidence.
>
> **Evidence gaps:** All support is rated “medium” and limited to metadata/abstract level without full‑text experimental confirmation. Graph‑based network data are absent. The immune and developmental links each rest on a single publication. Thus, the current synthesis highlights plausible associations but cannot establish definitive mechanisms or clinical utility. Further research, including full‑text appraisal and independent replication, is required to substantiate and extend these findings.

## AQ11: unknown_entity

**Question:** What is the consensus sequence length of TE-NOT-A-REAL-ELEMENT?

- Mode: DeepThink
- Completed: True
- End-to-end duration: 25,722 ms (25.7 s)
- Expected plugins: Entity Resolver, Sequence Plugin
- Actual plugins: Entity Resolver, Sequence Plugin
- Expected but not observed: None
- Request ID: `req_8fba4e25389c431a`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 5,984 ms (6.0 s) | 5,984 ms | ok |
| Planning | 1 | 5,112 ms (5.1 s) | 5,112 ms | ok |
| Executing | 1 | 3,435 ms (3.4 s) | 3,435 ms | ok |
| Writing | 1 | 10,933 ms (10.9 s) | 10,933 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | empty | 0 ms (0.0 s) | `{"resolved_entities":0,"alias_variants":0}` |
| Sequence Plugin | empty | 4 ms (0.0 s) | `{"matched_records":0,"strict_matches":0,"broad_matches":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: User asks for the consensus sequence length of the transposable element TE-NOT-A-REAL-ELEMENT.
2. **Understanding / artifact:** answer_goal: Provide the numerical length of the consensus sequence of TE-NOT-A-REAL-ELEMENT.
3. **Understanding / artifact:** warnings: The element name TE-NOT-A-REAL-ELEMENT may not correspond to a known transposable element; verification of its existence and sequence is necessary.
4. **Planning / artifact:** execution_goal: Retrieve the consensus sequence length for TE-NOT-A-REAL-ELEMENT using the Sequence Plugin to answer the user's question.
5. **Planning / artifact:** rationale: The user asks for consensus sequence length of a transposable element. The Sequence Plugin is designed to retrieve Repbase-backed sequence records, including consensus length, which directly matches the query. Other plugins are not needed because the question is purely about sequence properties, not literature, expression, genomic context, or graph relationships.
6. **Planning / artifact:** business_plugins: Sequence Plugin
7. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
8. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
9. **Executing / artifact:** reason: The question asks for the consensus sequence length of TE-NOT-A-REAL-ELEMENT. The Entity Resolver returned no resolved entities, so current evidence is empty. The Sequence Plugin is the only planned plugin that can retrieve Repbase-backed sequence records including consensus length. It has not been run yet and must be executed to gather the required evidence.
10. **Executing / artifact:** gaps: No evidence available for the consensus sequence length of TE-NOT-A-REAL-ELEMENT. The Sequence Plugin has not been called.
11. **Deep Think / tool_selected:** I will use Sequence Plugin to collect the next required evidence.
12. **Deep Think / tool_result:** Sequence Plugin completed. Scientific details are preserved below.
13. **Writing / artifact:** limitations: There was not enough direct structured or external evidence for a stronger answer.

### Complete Answer

> No consensus sequence length is available for TE-NOT-A-REAL-ELEMENT because it was not found in the Repbase database.

## AQ12: ambiguous_entity

**Question:** Introduce LINE-1 and explicitly state the entity scope used in your answer.

- Mode: DeepThink
- Completed: True
- End-to-end duration: 45,742 ms (45.7 s)
- Expected plugins: Entity Resolver
- Actual plugins: Entity Resolver, Graph Plugin, Sequence Plugin
- Expected but not observed: None
- Request ID: `req_fce3619cfa184115`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 11,137 ms (11.1 s) | 11,137 ms | ok |
| Planning | 1 | 15,572 ms (15.6 s) | 15,572 ms | ok |
| Executing | 2 | 10,753 ms (10.8 s) | 4,250, 6,503 ms | ok |
| Writing | 1 | 7,551 ms (7.6 s) | 7,551 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":3}` |
| Graph Plugin | empty | 525 ms (0.5 s) | `{"relations":0,"entity_types":0,"strict_matches":0,"broad_matches":0}` |
| Sequence Plugin | empty | 5 ms (0.0 s) | `{"matched_records":0,"strict_matches":0,"broad_matches":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / artifact:** question_summary: The user asks to introduce the entity LINE-1 and to explicitly state the entity scope used in the answer.
2. **Understanding / artifact:** answer_goal: Provide an introductory description of LINE-1 and explicitly define the entity scope (i.e., the specific entity and its recognized aliases or broad aliases) that is used in the answer.
3. **Understanding / artifact:** warnings: The answer must explicitly state the entity scope, such as which aliases (LINE1, LINE-1, LINE 1) and broad alias (L1) are considered, and clarify that the answer refers to the canonical entity LINE1.
4. **Planning / artifact:** execution_goal: Provide an introductory description of LINE-1 and explicitly define the entity scope used in the answer.
5. **Planning / artifact:** rationale: The user requests a general introduction to LINE-1. The Graph Plugin can retrieve known graph relations and properties for the LINE1 entity from the TE-KG, such as type, family, and associated targets. The Sequence Plugin can provide basic sequence facts like consensus length and ORF annotations, which are essential for a thorough introduction. The entity scope (aliases: LINE1, LINE-1, LINE 1; broad alias: L1) is already known from the understanding stage and will be explicitly stated in the answer. No other plugins are required as the question does not need literature, expression, genomic coordinates, or navigation. Citation Resolver is not needed because the answer will not reference specific citations.
6. **Planning / artifact:** business_plugins: Graph Plugin; Sequence Plugin
7. **Deep Think / tool_selected:** I will use Entity Resolver to collect the next required evidence.
8. **Deep Think / tool_result:** Entity Resolver completed. Scientific details are preserved below.
9. **Executing / artifact:** reason: The Graph Plugin is the next business plugin to run. It will retrieve known graph relations and properties for the LINE1 entity from the TE-KG, such as type, family, and associated targets. This is necessary for a comprehensive introduction. The Sequence Plugin will be run afterward to obtain sequence-related facts. Currently, only the Entity Resolver result is available, which resolved the entity and provided aliases.
10. **Executing / artifact:** gaps: No graph relations or properties for LINE1 have been retrieved yet.; No sequence information (consensus length, ORF annotations) has been retrieved yet.
11. **Deep Think / tool_selected:** I will use Graph Plugin to collect the next required evidence.
12. **Deep Think / tool_result:** Graph Plugin completed. Scientific details are preserved below.
13. **Executing / artifact:** reason: The Graph Plugin returned empty, so we need sequence facts (consensus length, ORF annotations) from the Sequence Plugin to provide a basic introduction. The Sequence Plugin is the remaining planned business plugin and can supply essential biological details about LINE-1 structure and features.
14. **Executing / artifact:** gaps: No sequence or structural information available yet.; No literature or citation evidence to support an introduction.; The current evidence is limited to entity resolution only.
15. **Deep Think / tool_selected:** I will use Sequence Plugin to collect the next required evidence.
16. **Deep Think / tool_result:** Sequence Plugin completed. Scientific details are preserved below.
17. **Writing / artifact:** limitations: There was not enough direct structured or external evidence for a stronger answer.; Both the Graph Plugin and Sequence Plugin returned empty results, so no biological relationships or sequence information are available.

### Complete Answer

> The entity scope used in this answer is the canonical transposable element entity **LINE1**, also known by its strict aliases: LINE1, LINE-1, and LINE 1, and by its broad alias L1. The supplied evidence only includes entity resolution; no graph relations or sequence data were retrieved from the Graph Plugin or Sequence Plugin. Therefore, a biological introduction to LINE-1 cannot be provided based solely on the available evidence.

## AQ13: research_report

**Question:** Write a concise research report on L1HS covering sequence, classification, representative genomic location, expression, disease associations, and literature evidence. State the data limitations explicitly.

- Mode: Agent
- Completed: True
- End-to-end duration: 494,040 ms (494.0 s)
- Expected plugins: Entity Resolver, Sequence Plugin, Tree Plugin, Genome Plugin, Expression Plugin, Graph Plugin, Literature Plugin, Literature Reading Plugin, Citation Resolver
- Actual plugins: Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin, Citation Resolver
- Expected but not observed: None
- Request ID: `req_5df5cb56475a748d`
- Errors: None

### Stage Timing

| Stage/call group | Calls | Total measured LLM time | Individual calls | Status |
|---|---:|---:|---|---|
| Understanding | 1 | 6,753 ms (6.8 s) | 6,753 ms | ok |
| Planning | 1 | 14,160 ms (14.2 s) | 14,160 ms | ok |
| Collecting | 1 | 5,549 ms (5.5 s) | 5,549 ms | ok |
| ExecutingReview | 5 | 303,658 ms (303.7 s) | 83,819, 69,700, 83,799, 32,437, 33,903 ms | ok |
| Sufficiency check | 1 | 10,157 ms (10.2 s) | 10,157 ms | ok |
| Answer structure | 1 | 15,003 ms (15.0 s) | 15,003 ms | contains error |
| Integrating | 1 | 23,216 ms (23.2 s) | 23,216 ms | ok |
| Writing decision | 1 | 23,867 ms (23.9 s) | 23,867 ms | ok |
| Final writing | 1 | 41,958 ms (42.0 s) | 41,958 ms | ok |

### Plugin Outcomes

| Plugin | Status | Plugin latency | Result counts |
|---|---|---:|---|
| Entity Resolver | ok | 0 ms (0.0 s) | `{"resolved_entities":1,"alias_variants":2}` |
| Literature Plugin | ok | 6,970 ms (7.0 s) | `{"local_hits":0,"strict_local_hits":0,"broad_local_hits":0,"pubmed_candidates":21,"reviewed":8}` |
| Literature Reading Plugin | ok | 41,286 ms (41.3 s) | `{"reviewed_count":8,"selected_count":8,"claim_clusters":3,"supported_claims":7,"conflicting_claims":0}` |
| Graph Plugin | ok | 156 ms (0.2 s) | `{"relations":12,"entity_types":1,"strict_matches":12,"broad_matches":0,"Disease":12}` |
| Tree Plugin | ok | 20 ms (0.0 s) | `{"paths":1}` |
| Expression Plugin | ok | 46 ms (0.0 s) | `{"profiles":1}` |
| Genome Plugin | ok | 1 ms (0.0 s) | `{"loci":1}` |
| Sequence Plugin | ok | 5 ms (0.0 s) | `{"matched_records":1,"strict_matches":1,"broad_matches":0}` |

### Visible Reasoning And Workflow Trace

1. **Understanding / node_llm_result:** User requests a concise research report on the L1HS retrotransposon, covering its sequence, classification, representative genomic location, expression, disease associations, and literature evidence, with explicit statement of data limitations.
2. **Question Understanding Node / analysis:** Recognized entities: L1HS via L1HS.
3. **Question Understanding Node / analysis:** Question type: literature. Complexity: single_hop_reasoning.
4. **Planning / node_llm_result:** Write a concise research report on L1HS covering sequence, classification, representative genomic location, expression, disease associations, and literature evidence. State the data limitations explicitly.
5. **Planning Node / planning_step:** Current knowledge gap: entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted..
6. **Planning Node / planning_step:** Current knowledge gap: literature evidence because the user explicitly asked for papers or literature support..
7. **Planning Node / planning_step:** Resolve the canonical identity and alias boundaries for L1HS.
8. **Planning Node / planning_step:** Collect evidence for entity normalization because the system must resolve stable canonical entities and alias chains before any evidence lookup can be trusted.
9. **Planning Node / planning_step:** Collect evidence for literature evidence because the user explicitly asked for papers or literature support.
10. **Collecting / node_llm_result:** No plugins have been executed yet. All evidence dimensions are missing. The primary routing path starts with Literature Plugin (Entity Resolver is bootstrap-only and not a business plugin). Literature Plugin will provide initial literature citations and baseline evidence for L1HS, enabling subsequent plugins to address other dimensions. Therefore, Literature Plugin is the required next step.
11. **Evidence Collection Node / tool_selected:** I will stabilize entity names first so later evidence lookup does not drift across aliases.
12. **Evidence Collection Node / tool_result:** These aliases will be reused by the graph, literature, genome, and sequence layers.
13. **Evidence Collection Node / reflection:** I resolved 1 entities and prepared 2 strict alias variants so the downstream plugins can retry stable names before considering broad aliases. Next queued tools: Literature Plugin, Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
14. **Evidence Collection Node / tool_selected:** I will add literature evidence now because the current question still needs direct citation support.
15. **ExecutingReview / node_llm_result:** The Literature Plugin executed a PubMed search for "L1HS" AND "expression" AND "sequence" and returned 8 citations. Key papers address L1 methylation profiling (PMID 36449162), antisense promoter activity (PMID 11238933), L1 promoter characterization (PMID 1701022), RUNX3 role in L1 transcription (PMID 12907736), and cell-type-specific L1 activation (PMID 27016617). Additional citations cover murine receptors (PMID 9714732, relevance uncertain), environmental effects on L1 transcription (PMID 11971989), and human-specific LINE-1 expression (PMID 9918768). No abstracts were retrieved, and the query did not explicitly cover classification, genomic location, or disease associations.
16. **Evidence Collection Node / tool_result:** These papers mainly cover mechanism, cancer relevance, and disease evidence, which is enough to support the next synthesis step.
17. **Evidence Collection Node / reflection:** I combined the local paper evidence with an external PubMed search, found 21 candidate records, and reviewed 8 citations that were worth carrying into the answer. Next queued tools: Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
18. **Evidence Collection Node / tool_selected:** I will synthesize the retrieved citations now so later steps receive grouped claims instead of a flat citation list.
19. **ExecutingReview / node_llm_result:** The Literature Reading Plugin reviewed 8 citations and synthesized 3 claim clusters: (1) L1HS promoter characterization and regulation by RUNX3 and steroid hormone-like agents, with 4 citations; (2) Cell-type specific activation and epigenetic regulation of L1, with 2 citations; (3) Human-specific L1 expression potentially essential for cell proliferation and cancer, with 1 citation. All claims have medium support strength and are based on metadata/abstract-level evidence.
20. **Evidence Collection Node / tool_result:** These grouped literature claims can be passed to later evidence synthesis or answer-writing nodes as JSON.
21. **Evidence Collection Node / reflection:** The literature reading layer reviewed 8 normalized citations and synthesized 3 claim clusters. Next queued tools: Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
22. **Evidence Collection Node / tool_selected:** I will check the local graph first because it is the strongest initial layer for entity normalization, literature evidence, structured disease relations, sequence and structure context, literature synthesis, classification context, expression context, genomic loci.
23. **ExecutingReview / node_llm_result:** The Graph Plugin returned 12 disease associations for L1HS, spanning general cancer, carcinoma, colorectal cancer, disturbed spermatogenesis, genetic disease, lung cancer, and lung squamous cell carcinoma. Detailed evidence items for 5 of these associations are provided with specific citations, linking L1HS hypomethylation and mobilization to these conditions. All relations are flagged as associations, not causal, with medium support strength. The data originates from a local graph and may not be exhaustive, but it supplies useful structured disease relations for further synthesis.
24. **Evidence Collection Node / tool_result:** These relations are enough for a first structured judgment, especially along Disease.
25. **Evidence Collection Node / reflection:** The local graph returned 12 structured relations, mainly across Disease. Next queued tools: Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
26. **Evidence Collection Node / tool_selected:** I will use the lineage tree now because classification context is still missing.
27. **Evidence Collection Node / tool_result:** These tree paths help locate the entity in its lineage, but mechanism questions still rely more on relation and literature evidence.
28. **Evidence Collection Node / reflection:** I resolved the classification context of the current entities. This helps with lineage background, although it is not the core evidence for the answer. Next queued tools: Expression Plugin, Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
29. **Evidence Collection Node / tool_selected:** I will inspect the expression layer now because expression context is still relevant.
30. **ExecutingReview / node_llm_result:** Expression Plugin returned three top expression contexts for L1HS: normal tissue (prostate gland), normal cell line (foreskin fibroblast), and cancer cell line (Anaplastic large cell lymphoma). The data is derived from internal expression profile datasets without associated citations, providing medium-confidence evidence.
31. **Evidence Collection Node / tool_result:** These expression summaries are better used as supporting context than as the core mechanism evidence.
32. **Evidence Collection Node / reflection:** I also checked the expression datasets and captured the top contexts for the recognized TEs. Next queued tools: Genome Plugin, Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
33. **Evidence Collection Node / tool_selected:** I will inspect the genome layer now because locus-level context is still relevant.
34. **Evidence Collection Node / tool_result:** These loci are most useful as genomic context or browser entry points.
35. **Evidence Collection Node / reflection:** I located representative genomic loci and browser entry points that can be used as supporting genomic context. Next queued tools: Sequence Plugin. Sufficiency: The research report still has required evidence layers that have not run.
36. **Evidence Collection Node / tool_selected:** I will inspect the sequence layer now because sequence-level facts are still required.
37. **ExecutingReview / node_llm_result:** The Sequence Plugin successfully matched L1HS to a Repbase-aligned record with a consensus length of 6064 bp and a partial sequence. Additional keyword-derived structure hints suggest LINE and LTR annotations, though the LTR hint is atypical for a non-LTR retrotransposon. Two Repbase citations support the record.
38. **Evidence Collection Node / tool_result:** These sequence-backed records add consensus length, annotation, and structure hints that can stabilize TE-specific answers.
39. **Evidence Collection Node / reflection:** I matched 1 TE sequence records from the Repbase-aligned library and extracted consensus length, sequence, and structure hints. No additional tools are currently queued. Sufficiency: All required evidence dimensions (sequence, classification, genomic location, expression, disease associations, literature evidence) have been collected through the executed plugins (Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin). The data covers sequence consensus and structure, classification hierarchy, representative genomic coordinates, expression profiles, disease relations, and literature citations, enabling a comprehensive research report with explicit limitation statements.
40. **Evidence Collection Node / tool_selected:** I will normalize the citation layer now so the final answer can cite stable records.
41. **Evidence Collection Node / tool_result:** These normalized citation records will be reused by the final answer and the front-end reference UI.
42. **Integrating / node_llm_result:** Claim-evidence map generated.
43. **Evidence Synthesis Node / synthesizing:** I am now synthesizing the resolved entities, 8 identified knowledge gaps, and 27 evidence items into a coherent answer. Tools used: Entity Resolver, Literature Plugin, Literature Reading Plugin, Graph Plugin, Tree Plugin, Expression Plugin, Genome Plugin, Sequence Plugin, Citation Resolver.
44. **WritingDecision / node_llm_result:** Compose an evidence audit report with sections: question scope, evidence inventory, citation assessment, gaps, and answer. Base the report strictly on the provided claim-evidence map, noting limitations explicitly. Use inline citations where literature PMIDs are available; for claims lacking direct literature, cite the evidence source and highlight the gap. Maintain a concise professional tone.

### Complete Answer

> **Question Scope**
>
> This report addresses a single-entity query about the human LINE-1 subfamily **L1HS** (L1HS‑Ta). It examines sequence, classification, representative genomic location, expression profiles, disease associations, and underlying literature, using an evidence audit format. All statements are grounded in the structured evidence package; no material beyond that package is introduced.
>
> **Evidence Inventory**
>
> *Sequence and classification*  
> L1HS maps to a Repbase‑backed consensus sequence of 6064 bp (`evidence_26`; Repbase records by Smit et al. 1995 and Jurka & Gentles 2005, cited as Repbase references). The record carries keyword‑derived structure hints (LTR, LINE), but these are not experimentally confirmed (`evidence_27`, low support). The taxonomic path is: TE → Retrotransposons → Non‑LTR Retrotransposons (LINEs) → L1 (LINE‑1) → L1PA → L1HS (`evidence_21`; no PMID).
>
> *Genomic location*  
> A representative genomic locus at **chr1:231,646,101‑231,652,225** (negative strand, length 6,124 bp) was retrieved from a bundle of 1,620 hits (`evidence_25`). This is a single exemplar; its biological relevance across the 1,620 copies is not validated.
>
> *Expression profiles*  
> Within the plugin‑supplied compendia, L1HS showed top expression in:
> - normal tissue: **prostate gland** (`evidence_22`; no associated PMID);
> - normal cell line: **foreskin fibroblast** (`evidence_23`; no PMID);
> - cancer cell line: **anaplastic large cell lymphoma** (`evidence_24`; no PMID).
>
> No statistical significance measures or effect sizes have been provided. These are single‑source, context‑specific observations.
>
> *Disease associations*  
> The Graph Plugin returned 12 BIO_RELATION associations (all with the quality flag *association not causality*). They encompass:
> - Cancer (via L1 mobilization) (PMID 25352549, 34425899) (`claim_9`);
> - Carcinoma (escape from DNA methylation) (PMID 36449162) (`claim_10`);
> - Colorectal cancer (excessive mutagenesis by human‑specific L1s) (PMID 22968929) (`claim_11`);
> - Disturbed spermatogenesis (L1HS hypomethylation) (PMID 38759652) (`claim_12`);
> - Genetic disease (potential to cause disease and occasional retrotransposition‑linked disorders) (PMID 29390960, 31853540) (`claims 13,14`);
> - Lung cancer and non‑small‑cell lung cancer (hypomethylation of L1Hs promoters in circulating DNA) (PMID 27565927) (`claims 15,18`);
> - Lung squamous cell carcinoma (highest total L1HS expression) (PMID 41681929) (`claim_16`);
> - Neural tube defects (L1Hs hypomethylation in neuronal tissues) (PMID 26122653) (`claim_17`);
> - Schizophrenia (L1HS transpositions as a genomic risk factor, preliminary evidence) (PMID 26990047) (`claim_19`);
> - Systemic lupus erythematosus (transcriptionally active L1Hs in neutrophils) (PMID 37165451) (`claim_20`).
>
> *Literature evidence (other)*  
> - **Genome‑wide methylation profiling** of young L1 elements by bs‑ATLAS‑seq (PMID 36449162) (`claim_1`);
> - **Antisense promoter** activity that drives adjacent cellular genes (PMID 11238933) (`claim_2`);
> - **Cell‑specific LINE‑1 promoter** characterization (PMID 1701022) (`claim_3`);
> - **RUNX3** role in L1 transcription and retrotransposition (PMID 12907736) (`claim_4`);
> - **Cell‑type‑dependent activation** restricted to permissive loci (PMID 27016617) (`claim_5`).
>
> The Literature Reading Plugin synthesised three themes: *L1HS promoter and regulatory mechanisms* (citations: PMID 11238933, 1701022, 12907736, 11971989; quality flag *metadata_or_abstract_level*) (`claim_6`); *cell‑type‑specific activation and epigenetic regulation* (PMID 36449162, 27016617; same quality flag) (`claim_7`); and *human‑specific expression and proliferation link* (PMID 9918768; same flag) (`claim_8`). The full‑text depth of these claims is uncertain as they are flagged *metadata_or_abstract_level*.
>
> **Citation Assessment**
>
> Of the 27 claims, 20 are supported by at least one PubMed citation (PMID) – covering literature records, graph associations (some PMIDs), and sequence‑derived Repbase references. Five claims – the classification path (`claim_21`), normal‑tissue expression (`claim_22`), normal‑cell‑line expression (`claim_23`), cancer‑cell‑line expression (`claim_24`), and representative genomic locus (`claim_25`) – lack direct PubMed identifiers; their support comes from Tree, Expression, and Genome plugins respectively. These are treated as plugin‑sourced evidence and are explicitly marked with their provenance. No claim appears without an evidence link; however, the evidence underlying expression and classification lacks independent literature validation, and the genomic locus is a single representative selection.
>
> **Gaps**
>
> The following limitations are explicit in the evidence package and are carried into this report:
>
> - Many literature‑derived claims originate from metadata/abstract‑level inspection (`metadata_or_abstract_level` flag); full‑text validation is missing.
> - All disease associations carry the `association_not_causality` flag and cannot be interpreted as causative.
> - Sequence structure hints (LTR, LINE) are keyword‑derived from Repbase metadata, not experimentally verified.
> - Expression data list only the top context per dataset without confidence intervals, statistical testing, or cross‑dataset replication.
> - The representative genomic locus is one of 1,620 hits; its biological significance is not validated.
> - The classification path (Tree Plugin) and expression profiles lack direct literature citations.
> - The consensus sequence length (6,064 bp) is based on Repbase; independent corroboration is not provided within this package.
> - Mechanistic details linking L1HS to specific diseases are not present.
> - Evidence for L1HS involvement in schizophrenia and systemic lupus erythematosus rests on single preliminary studies.
> - The `route_map` is empty, precluding any integrative multi‑endpoint analysis.
>
> **Answer**
>
> L1HS is the human‑specific, currently active subfamily of LINE‑1 retrotransposons, classified within the L1PA branch. Its consensus sequence is 6,064 bp (Repbase) and it is represented genome‑wide, with an exemplar at chr1:231,646,101‑231,652,225. Expression compendia indicate high transcript levels in prostate gland, foreskin fibroblast, and anaplastic large cell lymphoma, but these findings are single‑context and lack statistical quantification. Published literature (PMID‑level) documents a cell‑type‑specific promoter with antisense activity, regulation by RUNX3 and steroid‑hormone‑like agents, dependence on permissive loci, and a methylation‑sensitive activation pattern particularly in carcinomas and lung cancers. Graph‑derived associations connect L1HS to a broad range of conditions – cancer, colorectal cancer, lung cancer, LSQCC, neural tube defects, disturbed spermatogenesis, genetic disease, schizophrenia, and SLE – all marked as association, not causation. Limitations are significant: most literature interpretation remains at the abstract/metadata level; expression and classification evidence lack independent PMID anchors; disease links are associational and in several instances preliminary; and no mechanistic causation is established. Therefore, while L1HS is an extensively observed, potentially pathogenic transposable element, the current evidence base allows only associative and context‑limited conclusions.
